Clenoliximab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Clenoliximab ?
Monoclonal antibody
Type Whole antibody
Source Chimeric (primate/human)
Target CD4
Clinical data
Legal status
?
Identifiers
CAS number  YesY
ATC code None
Chemical data
Formula ?
 N (what is this?)  (verify)

Clenoliximab (INN[1]) is a monoclonal antibody against CD4. It acts as an immunomodulator and has been investigated for the treatment of rheumatoid arthritis.[2] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[1]

References[edit]

  1. ^ a b World Health Organization (1997). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77". WHO Drug Information 11 (2): 89. 
  2. ^ Hepburn, TW; Totoritis, MC; Davis, CB (2003). "Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis.". Rheumatology (Oxford, England) 42 (1): 54–61. doi:10.1093/rheumatology/keg030. PMID 12509613.